SYNCHRONY FINANCIAL (“Synchrony”) announced that the underwriters for
its initial public offering of common stock have partially exercised
their option to purchase additional shares and purchased an additional
NATICK, Mass., June 30, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 397,087 shares of its common stock at a price of $42.50 per share before underwriting discounts.
NOVATO, Calif., July 14, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the closing of its public offering of 2,319,951 shares of common stock at a price to the public of $40.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 302,602 additional shares of common stock.
Signature Bank (Nasdaq: SBNY), a New York-based full service commercial
bank, announced today that J.P. Morgan, the investment bank that acted
as sole bookrunner in its recent public stock offering, which closed on
June 13, 2014, exercised in full the option the Bank had granted the
firm to purchase up to 315,000 additional shares of common stock.
Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products today reaffirms its guidance issued on its
earnings call on September 4, 2014 in conjunction with the announcement
of the underwriters’ exercise of its option to purchase additional
shares in connection with the Initial Public Offering.
The board of directors of Phillips 66 (NYSE: PSX), an energy
manufacturing and logistics company, has approved an increase in 2014
capital spending to support the company’s growth strategy and authorized
returning additional capital to shareholders.
Insmed Incorporated (Nasdaq:INSM) announced the closing of a $115.1
million underwritten public offering of 10,235,000 shares of common
stock, including 1,335,000 shares of common stock which were issued
pursuant to the exercise of the underwriters' option to purchase
additional shares, at a price of $11.25 per share to the public.
SANTA MONICA, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) , a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that the underwriters of its previously announced initial public offering have exercised in full their option to purchase an additional 1,125,000 shares of Kite Pharma's common stock at the public offering price of $17.00 per share, less customary underwriting discounts and commissions.
HealthEquity, Inc. (Nasdaq: HQY), one of the largest U.S. Health Savings
Account non-bank custodians, today announced that the underwriters of
its previously announced initial public offering of 9,100,000 shares of
common stock exercised in full their over-allotment option to purchase
an additional 1,365,000 shares of common stock from HealthEquity at the
initial public offering price of $14.00 per share, less customary
underwriting discounts and commissions.
Pebblebrook Hotel Trust (NYSE: PEB) (the “Company”) today announced that
it has closed its previously announced public follow-on offering of
3,450,000 of its common shares, including 450,000 common shares issued
pursuant to the full exercise of the underwriter’s option to purchase
additional common shares, for net proceeds of approximately $131.4
million, after deducting estimated offering-related expenses.
NEWARK, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) , a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the closing of its follow-on public offering of 4,600,000 shares of common stock at a public offering price of $30.50 per share.
LA JOLLA, Calif., July 16, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX) , a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, announced today the completion of its underwritten public offering of 3,622,500 shares of its common stock at a public offering price of $19.25 per share.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.